» Articles » PMID: 1995956

Respiratory Syncytial Virus (RSV) F, G, M2 (22K), and N Proteins Each Induce Resistance to RSV Challenge, but Resistance Induced by M2 and N Proteins is Relatively Short-lived

Overview
Journal J Virol
Date 1991 Mar 1
PMID 1995956
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

The ability of recombinant vaccinia viruses that separately encoded 9 of the 10 known respiratory syncytial virus (RSV) proteins to induce resistance to RSV challenge was studied in BALB/c mice. Resistance was examined at two intervals following vaccination to examine early (day 9) as well as late (day 28) immunity. BALB/c mice were inoculated simultaneously by the intranasal and intraperitoneal routes with a recombinant vaccinia virus encoding one of the following RSV proteins: F, G, N, P, SH, M, 1B, 1C, or M2 (22K). A parainfluenza virus type 3 HN protein recombinant (Vac-HN) served as a negative control. One half of the mice were challenged with RSV intranasally on day 9, and the remaining animals were challenged on day 28 postvaccination. Mice previously immunized by infection with RSV, Vac-F, or Vac-G were completely or almost completely resistant to RSV challenge on both days. In contrast, immunization with Vac-HN, -P, -SH, -M, -1B, or -1C did not induce detectable resistance to RSV challenge. Mice previously infected with Vac-M2 or Vac-N exhibited significant but not complete resistance on day 9. However, in both cases resistance had largely waned by day 28 and was detectable only in mice immunized with Vac-M2. These results demonstrate that F and G proteins expressed by recombinant vaccinia viruses are the most effective RSV protective antigens. This study also suggests that RSV vaccines need only contain the F and G glycoproteins, because the immunity conferred by the other proteins is less effective and appears to wane rapidly with time.

Citing Articles

Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate ΔNS2/Δ1313/I1314L increase the stability of infectivity and content of prefusion F protein.

Alamares-Sapuay J, Kishko M, Lai C, Parrington M, Delagrave S, Herbert R PLoS One. 2024; 19(4):e0301773.

PMID: 38593167 PMC: 11003679. DOI: 10.1371/journal.pone.0301773.


Development and comparison of immunologic assays to detect primary RSV infections in infants.

Anderson L, Jadhao S, Hussaini L, Ha B, McCracken C, Gibson T Front Immunol. 2024; 14:1332772.

PMID: 38283339 PMC: 10811012. DOI: 10.3389/fimmu.2023.1332772.


Cationic-nanogel nasal vaccine containing the ectodomain of RSV-small hydrophobic protein induces protective immunity in rodents.

Umemoto S, Nakahashi-Ouchida R, Yuki Y, Kurokawa S, Machita T, Uchida Y NPJ Vaccines. 2023; 8(1):106.

PMID: 37488116 PMC: 10366164. DOI: 10.1038/s41541-023-00700-3.


A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 Years of Age.

Cheng X, Zhao G, Dong A, He Z, Wang J, Jiang B Vaccines (Basel). 2023; 11(5).

PMID: 37243103 PMC: 10221330. DOI: 10.3390/vaccines11050999.


Functional Features of the Respiratory Syncytial Virus G Protein.

Anderson L, Jadhao S, Paden C, Tong S Viruses. 2021; 13(7).

PMID: 34372490 PMC: 8310105. DOI: 10.3390/v13071214.


References
1.
Iwata H, Tagaya M, Matsumoto K, Miyadai T, Yokochi T, Kimura Y . Aerosol vaccination with a sendai virus temperature-sensitive mutant (HVJ-pB) derived from persistently infected cells. J Infect Dis. 1990; 162(2):402-7. DOI: 10.1093/infdis/162.2.402. View

2.
Openshaw P, Anderson K, Wertz G, Askonas B . The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. J Virol. 1990; 64(4):1683-9. PMC: 249305. DOI: 10.1128/JVI.64.4.1683-1689.1990. View

3.
Nicholas J, Rubino K, Levely M, Adams E, Collins P . Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J Virol. 1990; 64(9):4232-41. PMC: 247888. DOI: 10.1128/JVI.64.9.4232-4241.1990. View

4.
Murphy B, Sotnikov A, Lawrence L, Banks S, Prince G . Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine. 1990; 8(5):497-502. DOI: 10.1016/0264-410x(90)90253-i. View

5.
Prince G, Jenson A, Horswood R, Camargo E, Chanock R . The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol. 1978; 93(3):771-91. PMC: 2018360. View